01Jul
Novartis and Alcon FCPA Enforcement Action: Lessons Learned (Part III of III)
At the outset, Novartis is “lucky” – the settlement is relatively positive, despite its 2016 SEC enforcement action in China. Given Novartis weak culture of compliance (if anything, a better description may be a culture of non-compliance) and its status as a recidivist, Novartis could have been slammed with a stiffer enforcement action, including assignment of an independent corporate compliance monitor and a higher penalty. ...
By:
Michael Volkov
Related
Once the claimant’s condition is at maximum medical improvement, the Maryland statute provides for ...
Read More >
On Friday, August 9, 2019, the National Labor Relations Board (“NLRB” or “Board”) issued its fir...
Read More >
Given the ongoing developments with the Coronavirus outbreak, we want to provide you with simple pro...
Read More >
On September 18, 2019, Governor Newsom signed Assembly Bill 5, thereby establishing a law that purpo...
Read More >
What constitutes sexual harassment? In the Hungarian law, sexual harassment is covered by the gener...
Read More >
In Western Standard, LLC, v. SourceHOV Holdings, Inc. and Pangea Acquisitions, Inc., C.A. No. 2018-0...
Read More >